Fewer than one in 10 individuals eligible to benefit from obesity jabs like Wegovy have access to them, warns the global health agency as it publishes its first guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for increased and just access to this class of drugs.
Per forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidance acknowledges that obesity is a long-term condition that can be treated with comprehensive and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the treatments that can assist patients in reducing significant weight, explains the agency.
Skinny Jab Scarcity
Despite the present most favorable outlook, the production of such drugs could only cover around 100 million people – fewer than 10% of eligible patients, according to the WHO.
The advice urges countries and companies to increase availability, by strategies including voluntary licensing.
Exclusive production rights on semaglutide – the core component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Injections Function
These medications replicate a natural hormone to reduce digestion speed, suppress the appetite and enhance satiety so individuals reduce food intake.
Individuals commonly see weight reduction after several weeks of commencing the regular doses.
Research suggests patients may put most of the weight back on within a year of stopping the drug, when their normal food cravings resume.
Being carrying excess weight elevates your chance for developing health problems, such as type 2 diabetes, heart disease, stroke, and some cancers.
Excess weight concerns individuals in every country and was associated with millions of deaths worldwide in 2024, per the health agency.
